INS and Hypoglycemia: Another study demonstrated that acute inhibition of SGLT1/SGLT2 with canagliflozin (high dose of 600 mg) in 10 patients treated with RYGB attenuated the early increase in GLP-1, GIP, and plasma insulin after glucose ingestion (50 g), with a later increase in glucagon concentrations, producing combined effects that could lead to a lower risk of postprandial hypoglycemia [106].